Sandbox:M.B

WikiDoc Resources for Sandbox:M.B
Articles
Most recent articles on Sandbox:M.B Most cited articles on Sandbox:M.B Review articles on Sandbox:M.B Articles on Sandbox:M.B in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sandbox:M.B Images of Sandbox:M.B Photos of Sandbox:M.B Podcasts & MP3s on Sandbox:M.B Videos on Sandbox:M.B
Evidence Based Medicine
Cochrane Collaboration on Sandbox:M.B Bandolier on Sandbox:M.B TRIP on Sandbox:M.B
Clinical Trials
Ongoing Trials on Sandbox:M.B at Clinical Trials.gov Trial results on Sandbox:M.B Clinical Trials on Sandbox:M.B at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sandbox:M.B NICE Guidance on Sandbox:M.B NHS PRODIGY Guidance FDA on Sandbox:M.B CDC on Sandbox:M.B
Books
Books on Sandbox:M.B
News
Sandbox:M.B in the news Be alerted to news on Sandbox:M.B News trends on Sandbox:M.B
Commentary
Blogs on Sandbox:M.B
Definitions
Definitions of Sandbox:M.B
Patient Resources / Community
Patient resources on Sandbox:M.B Discussion groups on Sandbox:M.B Patient Handouts on Sandbox:M.B Directions to Hospitals Treating Sandbox:M.B Risk calculators and risk factors for Sandbox:M.B
Healthcare Provider Resources
Symptoms of Sandbox:M.B Causes & Risk Factors for Sandbox:M.B Diagnostic studies for Sandbox:M.B Treatment of Sandbox:M.B
Continuing Medical Education (CME)
CME Programs on Sandbox:M.B
International
Sandbox:M.B en Espanol Sandbox:M.B en Francais
Business
Sandbox:M.B in the Marketplace Patents on Sandbox:M.B
Experimental / Informatics
List of terms related to Sandbox:M.B

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Synonyms and keywords:

Special consideration when adding information from observational studies

Template Sentence for Observational Study
“Among (number of/other important demographic information) patients in (location), (exposure) was associated with (outcome) in observational data” (REF)
Example: Among 459 adult male diabetic patients in the United States, COVID-19 exposure was associated with abdominal pain in observational data (REF)

Overview

Systemic lupus erythematous (SLE) is an autoimmune disease (when immune system attacks your own body tissues)

Historical Perspective

Systematic Lupus Erythematous (SLE) was first discovered by Rogerius, an Italian physician, in 12th century to describe the facial lesions of lupus .

The association between sunlight and Lupus was made 19th century.

In 1907, Rasce was the first to discover the association between sunlight and the development of Lupus.

In 1984, genetic predisposition was first implicated in the pathogenesis of lupus.

In 1982, eleven criteria were developed by American College of Rheumatology (ACR) to diagnose SLE.

Classification

SLE has been classified based on different criteria, such as dermatologic symptoms , renal involvement, and clinical characteristics. Dermatologic classification

Acute cutaneous lupus erythematosus (ACLE)

Subacute cutaneous lupus erythematosus (SCLE)

Chronic cutaneous lupus erythematosus (CCLE)

Intermittent cutaneous lupus erythematosus (ICLE)

classification based on disease characteristics

Systemic lupus erythematosus (SLE)

Cutaneous lupus erythematosus (CLE)

Drug-induced lupus

Neonatal lupus

classification based on renal microscopic features

International society of nephrology classified lupus nephritis into six classes based on microscopic findings:

I: Minimal mesangial lupus nephritis

II: Mesangial proliferative lupus nephritis

III: Focal lupus nephritis

IV: Diffuse lupus nephritis

V: Lupus membranous nephropathy

VI: Advanced sclerosing lupus nephritis

Pathophysiology

SLE is a chronic inflammatory disease which is classified as a type III hypersensitivity reaction. In SLE body produces antibodies against itself proteins, particularly cell nucleus proteins. SLE can be triggered by environmental factors. The exact pathogenesis of [disease name] is not fully understood. SLE patients have severe polyclonal B-cell activation, with considerable immature B cells. Memory B cells with increased CD27+/IgD—are less susceptible to immunosuppression. CD27-/IgD- memory B cells are associated with increased disease activity and renal lupus. T cells, which regulate B-cell responses and infiltrate target tissues, have defects in signaling, adhesion, co-stimulation, gene transcription, and alternative splicing. The cytokines B-lymphocyte stimulator (BAFF), interleukins (6, 17, 18), type I interferons, and tumor necrosis factor α (TNFα) are involved in the inflammatory process. In addition, low level of C3 is associated with this disease.

Causes

Patients with SLE usually have a genetic susceptibility which is triggered by environmental factors. However, no single gene is identified to cause SLE and multiple genes have been found to be associated with this disease. Vitamin D deficiency has been shown to be one of the triggers, such as SLE classes I, II, III. Genes which have been found to date, are IRF5, PTPN22, STAT4,BANK1, ITGAM, BLK, TNFSF4 and CDKN1A. Therefore, SLE is considered an oligogenic trait.

Drug-induced lupus and cutaneous lupus (Discoid lupus erythematous) are the other two forms of lupus. Near 40 medications can induce lupus, among which procainamide, isoniazid, hydralazine, quinidine, and phenytoin are the most famous ones.

Differentiating ((Page name)) from other Diseases

Since SLE involves several organs, it has a long list of differential diagnosis, such as adult onset still disease, sarcoidosis, Behcet disease, psoriatic arthritis, endocarditis, rheumatoid arthritis, chronic fatigue syndrome, fibromyalgia, HIV infection, mixed connective tissue disease, lyme disease, and reactive arthritis.

Epidemiology and Demographics

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.

OR

In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

OR

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.

Patients of all age groups may develop [disease name].

OR

The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.

OR

[Disease name] commonly affects individuals younger than/older than [number of years] years of age.

OR

[Chronic disease name] is usually first diagnosed among [age group].

OR

[Acute disease name] commonly affects [age group].

There is no racial predilection to [disease name].

OR

[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

[Disease name] affects men and women equally.

OR

[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

The majority of [disease name] cases are reported in [geographical region].

OR

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Risk Factors

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

Template:WikiDoc Sources